重症COVID-19患者的死亡率降低24%!Leronlimab显功效

2021-03-08 Allan MedSci原创

生物技术公司CytoDyn正在开发Vyrologix™(leronlimab-PRO 140),这是一种具有多种治疗适应症的CCR5拮抗剂。

生物技术公司CytoDyn正在开发Vyrologix™(leronlimab-PRO 140),这是一种具有多种治疗适应症的CCR5拮抗剂。如今,leronlimab治疗重症COVID-19患者的III期试验证明,leronlimab具有持续安全性,能够显著提高患者生存率并加快出院速度。该试验的数据已报告给美国食品药品监督管理局(FDA)、英国药物与保健产品监管局(MHRA)和加拿大卫生部(HC)。

该危重人群的试验数据主要包括以下内容:1)与安慰剂组相比,leronlimab组的全因死亡率(研究的主要终点)降低了24%;2)与安慰剂组相比,leronlimab组患者的平均住院时间减少了6天;3)此外,leronlimab组患者在第28天出院的可能性更高(28%比11%),比安慰剂组高166%。

CytoDyn首席医学官Scott A. Kelly博士指出:“我们认为,这进一步支持CCR5作为免疫调节的治疗靶点,leronlimab介导的CCR5阻断能够破坏CCL5-CCR5轴的促炎性反应,这是重症COVID-19患者细胞因子风暴的重要机制”。

 

原始出处:

https://www.firstwordpharma.com/node/1807095?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912564, encodeId=4c2a19125649a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 14 04:51:22 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001228, encodeId=395b100122807, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62135377320, createdName=ms9000001777776754, createdTime=Tue Jul 20 20:14:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953862, encodeId=941095386205, content=学习好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/h4m2huWViaU2oROzjw4uu7iaEpQwwRhogLI8Xt6OOsz6xiaibL3C5bjWtwdJhzNUGm3EKIpmiaOp3ZK9uSwrJ6t9hpw/132, createdBy=bb9e5262905, createdName=杏林王艾伦, createdTime=Mon Apr 05 07:55:52 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297517, encodeId=e583129e51713, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Mar 10 01:51:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946379, encodeId=f9359463e9c8, content=新冠患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Mon Mar 08 12:56:32 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946345, encodeId=30fd946345c7, content=好文章,共享之。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Mar 08 10:58:19 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-10-14 snf701207
  2. [GetPortalCommentsPageByObjectIdResponse(id=1912564, encodeId=4c2a19125649a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 14 04:51:22 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001228, encodeId=395b100122807, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62135377320, createdName=ms9000001777776754, createdTime=Tue Jul 20 20:14:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953862, encodeId=941095386205, content=学习好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/h4m2huWViaU2oROzjw4uu7iaEpQwwRhogLI8Xt6OOsz6xiaibL3C5bjWtwdJhzNUGm3EKIpmiaOp3ZK9uSwrJ6t9hpw/132, createdBy=bb9e5262905, createdName=杏林王艾伦, createdTime=Mon Apr 05 07:55:52 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297517, encodeId=e583129e51713, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Mar 10 01:51:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946379, encodeId=f9359463e9c8, content=新冠患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Mon Mar 08 12:56:32 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946345, encodeId=30fd946345c7, content=好文章,共享之。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Mar 08 10:58:19 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-07-20 ms9000001777776754

    1

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1912564, encodeId=4c2a19125649a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 14 04:51:22 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001228, encodeId=395b100122807, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62135377320, createdName=ms9000001777776754, createdTime=Tue Jul 20 20:14:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953862, encodeId=941095386205, content=学习好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/h4m2huWViaU2oROzjw4uu7iaEpQwwRhogLI8Xt6OOsz6xiaibL3C5bjWtwdJhzNUGm3EKIpmiaOp3ZK9uSwrJ6t9hpw/132, createdBy=bb9e5262905, createdName=杏林王艾伦, createdTime=Mon Apr 05 07:55:52 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297517, encodeId=e583129e51713, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Mar 10 01:51:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946379, encodeId=f9359463e9c8, content=新冠患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Mon Mar 08 12:56:32 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946345, encodeId=30fd946345c7, content=好文章,共享之。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Mar 08 10:58:19 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-04-05 杏林王艾伦

    学习好资料

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1912564, encodeId=4c2a19125649a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 14 04:51:22 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001228, encodeId=395b100122807, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62135377320, createdName=ms9000001777776754, createdTime=Tue Jul 20 20:14:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953862, encodeId=941095386205, content=学习好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/h4m2huWViaU2oROzjw4uu7iaEpQwwRhogLI8Xt6OOsz6xiaibL3C5bjWtwdJhzNUGm3EKIpmiaOp3ZK9uSwrJ6t9hpw/132, createdBy=bb9e5262905, createdName=杏林王艾伦, createdTime=Mon Apr 05 07:55:52 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297517, encodeId=e583129e51713, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Mar 10 01:51:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946379, encodeId=f9359463e9c8, content=新冠患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Mon Mar 08 12:56:32 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946345, encodeId=30fd946345c7, content=好文章,共享之。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Mar 08 10:58:19 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1912564, encodeId=4c2a19125649a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 14 04:51:22 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001228, encodeId=395b100122807, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62135377320, createdName=ms9000001777776754, createdTime=Tue Jul 20 20:14:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953862, encodeId=941095386205, content=学习好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/h4m2huWViaU2oROzjw4uu7iaEpQwwRhogLI8Xt6OOsz6xiaibL3C5bjWtwdJhzNUGm3EKIpmiaOp3ZK9uSwrJ6t9hpw/132, createdBy=bb9e5262905, createdName=杏林王艾伦, createdTime=Mon Apr 05 07:55:52 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297517, encodeId=e583129e51713, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Mar 10 01:51:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946379, encodeId=f9359463e9c8, content=新冠患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Mon Mar 08 12:56:32 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946345, encodeId=30fd946345c7, content=好文章,共享之。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Mar 08 10:58:19 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-03-08 科研科研科研

    新冠患者

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1912564, encodeId=4c2a19125649a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 14 04:51:22 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001228, encodeId=395b100122807, content=1, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62135377320, createdName=ms9000001777776754, createdTime=Tue Jul 20 20:14:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953862, encodeId=941095386205, content=学习好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/h4m2huWViaU2oROzjw4uu7iaEpQwwRhogLI8Xt6OOsz6xiaibL3C5bjWtwdJhzNUGm3EKIpmiaOp3ZK9uSwrJ6t9hpw/132, createdBy=bb9e5262905, createdName=杏林王艾伦, createdTime=Mon Apr 05 07:55:52 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297517, encodeId=e583129e51713, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Mar 10 01:51:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946379, encodeId=f9359463e9c8, content=新冠患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210110/e6124a4b19bc40ce8afaae096d21126b/dd778ac260c9416eb87e7d08139507f5.jpg, createdBy=4d2f5079605, createdName=科研科研科研, createdTime=Mon Mar 08 12:56:32 CST 2021, time=2021-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946345, encodeId=30fd946345c7, content=好文章,共享之。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Mar 08 10:58:19 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-03-08 yangchou

    好文章,共享之。

    0

相关资讯

BJU Int:医院手术量与膀胱癌根治术治疗后的死亡率有关

最近,有研究人员通过评估医院手术量(HV)与术后死亡率之间的关系,促进了关于医院应进行的根治性膀胱切除术(RCs)最低手术量的辩论。

Lancet Diabetes Endocrinology:2001-18年糖尿病患者和非糖尿病个体的死亡原因变化

在英国和其他高收入国家中,糖尿病的发病率持续上升,但心血管疾病的死亡率却大大下降!然而,目前关于这些趋势如何改变了既往主要死于血管病的糖尿病患者的死亡原因的数据很少。本研究评估了糖尿病患者的全因死亡率

Sci Rep:56个国家的肾癌死亡率与发病率之比的趋势

肾癌(KC)的发病率和死亡率正在上升。然而,在过去的十年里,各地区的死亡率趋势各不相同,这可能是由于医疗环境的差异所致,如高频的影像检查和有效的全身治疗的可用性。事实证明,这两种医疗方案的提供与KC的

JCEM:血钠异常是COVID-19住院患者发病率和死亡率的预测指标

住院期间血钠异常是COVID-19患者预后不良的危险因素,高钠血症和低钠血症分别与更大的死亡和呼吸衰竭风险相关。血钠水平可用于COVID-19患者的危险分层。

拓展阅读

Biomedicines:2型糖尿病住院患者COVID-19的长期预后

在T2D合并COVID-19患者中,随访观察到住院死亡率、卒中和心血管住院率增加。

Cureus:2型糖尿病状态、糖尿病并发症严重程度指数评分及其与COVID-19严重程度的关系

与非糖尿病患者相比,我们样本中的糖尿病患者发生COVID-19不良临床结果和住院死亡率的几率更高。

Lancet Infect Dis:口服VV116用于治疗轻中度COVID-19成人患者的有效性和安全性评价

目前,治疗COVID-19的医疗需求仍未得到满足,新型抗病毒药物-VV116可用于治疗轻中度COVID-19成人患者,能够显著缩短临床症状持续时间,与其他药物较少发生药物间相互作用,且安全性良好。

论文解读|Yihua Wang教授团队新研究揭示了揭示COVID-19对肺癌治疗和研究的深远影响

该文章揭示了此次大流行对肺癌治疗、临床试验、研究活动的影响。

JAMA Intern Med:COVID-19相关急性肾损伤与长期肾脏结果

与患有其他疾病相关AKI的患者相比,COVID-AKI住院幸存者的MAKE发生率、长期肾功能下降和死亡率均显著较低。

【解读分享】2024 PIDS共识声明:儿童和青少年COVID-19预防和管理指南

本文主要针对儿童和青少年COVID-19预防和管理提供指导建议,涉及COVID-19的危险分层、治疗和预防,点击即可下载查看。